-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CWLYxGZYBAlVb2M428KdhUXEj3JvW2YKo3lGHymi5DO8E0Ya54yAEksFXMkGF8V0 g+rYvgg61PCkaUqyYHBo4A== 0001193125-04-207303.txt : 20050706 0001193125-04-207303.hdr.sgml : 20050706 20041203160541 ACCESSION NUMBER: 0001193125-04-207303 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20041203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OSCIENT PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: GENOME THERAPEUTICS CORP DATE OF NAME CHANGE: 19941215 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm ACCELERATION REQUEST

Oscient Pharmaceuticals Corporation

1000 Winter Street, Suite 2200

Waltham, MA 02451

 

December 3, 2004

 

Mr. Gregory S. Belliston

Division of Corporation Finance

United States Securities and Exchange Commission

450 Fifth Street, N.W.

Washington, D.C. 20549

 

Re: Oscient Pharmaceuticals Corporation.—Request for Acceleration of Effectiveness

of Registration Statement on Form S-3 (File No. 333-118026)

 

Dear Mr. Belliston:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oscient Pharmaceuticals Corporation (the “Company”), hereby requests that the Company’s Registration Statement on Form S-3 (File No. 333-118026) be declared effective at 4 p.m. Eastern Time on December 6, 2004 or as soon as possible thereafter.

 

The Company acknowledges that (i) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any actions with respect to the filing, (ii) the action of the Commission or the staff pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing, and (iii) the Company may not assert this action as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

Please call Matthew Choate of Ropes & Gray LLP at (617) 951-7153 if you have any questions. Thank you for your assistance.

 

 

 

Very truly yours,

 

 

OSCIENT PHARMACEUTICALS CORPORATION
By:   /S/    STEVEN M. RAUSCHER
   

Name: Steven M. Rauscher

Title: President and Chief Executive Officer

 -----END PRIVACY-ENHANCED MESSAGE-----